2046-19-7

Basic information

• Product Name: D-2-AMINO-5-PHENYL-PENTANOIC ACID
• Synonyms: (R)-2-AMINO-5-PHENYL-PENTANOIC ACID;H-D-NVA(5-PHENYL)-OH;D-2-AMINO-5-PHENYL-PENTANOIC ACID;D-Nva(5-phenyl)-OH;D-PEA;Benzenepentanoic acid, .alpha.-amino-
• CAS NO: 2046-19-7
• Molecular Formula: C11H15NO2
• Molecular Weight: 193.24
• Product Categories: Phenylalanine analogs and other aromatic alpha amino acids;a-amino
• Mol File: 2046-19-7.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 375.2 °C at 760 mmHg
• Flash Point: 180.7 °C
• Appearance: /
• Density: 1.133 g/cm³
• Vapor Pressure: 2.69E-06mmHg at 25°C
• Refractive Index: 1.555
• Sensitive: Air Sensitive
• CAS DataBase Reference: D-2-AMINO-5-PHENYL-PENTANOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: D-2-AMINO-5-PHENYL-PENTANOIC ACID(2046-19-7)
• EPA Substance Registry System: D-2-AMINO-5-PHENYL-PENTANOIC ACID(2046-19-7)

Safety Data

• Hazardous Substances Data: 2046-19-7(Hazardous Substances Data)

Usage

Uses

Used in Scientific Research:
D-2-Amino-5-Phenyl-Pentanoic Acid is used as a research compound for investigating the roles and functions of amino acids in biological systems. Its unique structure with an aromatic phenyl group allows researchers to explore its interactions and effects within various biological processes.
Used in Pharmaceutical Development:
While still in the research phase, D-2-Amino-5-Phenyl-Pentanoic Acid may have potential applications in the development of pharmaceuticals, particularly in areas where its specific properties could be leveraged for therapeutic purposes. Further research is needed to determine its suitability and efficacy in such applications.
Used in Chemical Synthesis:
D-2-Amino-5-Phenyl-Pentanoic Acid may also be used as a building block or intermediate in the synthesis of more complex molecules, such as drugs or other bioactive compounds. Its aromatic phenyl group could be a key component in the creation of novel chemical entities with potential applications in various industries.

InChI:InChI=1/C11H15NO2/c12-10(11(13)14)8-4-7-9-5-2-1-3-6-9/h1-3,5-6,10H,4,7-8,12H2,(H,13,14)

Upstream product

• 101599-51-3 formylamino-(3-phenyl-propyl)-malonic acid diethyl ester 
• 84299-75-2 2-bromo-5-phenyl-valeric acid 
• 4392-24-9 Cinnamyl bromide 
• 108019-30-3 DL-N-acetyl-2-amino-5-phenylpentanoic acid 
• 52161-76-9 (E,2S)-2-amino-5-phenyl-pent-4-enoic acid 
• 52161-73-6 2-acetylamino-2-(3-phenyl-propyl)malonic acid diethyl ester 
• 81867-09-6 ethyl 2-oxo-5-phenylpentanoate 
• 637-59-2 1-Bromo-3-phenylpropane 
• 852298-85-2 (4S,5R)-1-((S)-2-Azido-5-phenyl-pentanoyl)-3,4-dimethyl-5-phenyl-imidazolidin-2-one 
• 852298-77-2 (4S,5R)-1-((R)-2-Bromo-5-phenyl-pentanoyl)-3,4-dimethyl-5-phenyl-imidazolidin-2-one 
• 852298-94-3 (S)-2-Azido-5-phenyl-pentanoic acid 
• 121704-10-7 2-(2-Methoxy-acetylamino)-5-phenyl-pentanoic acid 
• 88768-11-0 2-oxo-5-phenylpentanoic acid 
• 62732-55-2 2-Acetylamino-2-(3-phenyl-propyl)-malonic acid 

Downstream Products

• 400886-12-6 (S)-2-Amino-5-phenyl-pentanoic acid allyl ester 
• 110849-10-0 2-(t-butoxycarbonylamino)-5-phenylpentanoic acid 

Relevant articles and documents

Effective synthesis of optically active 3-phenyl-3-(3-trifluoromethyl) diazirinyl bishomophenylalanine derivatives

Effective incorporation of phenyldiazirine moiety on the acyl residue of L- and D- glutamic acid by Friedel-Crafts reactions with triflic acid developed simple preparation of bishomophenylalanine (bhPhe) for aromatics, which added a

Synthesis method of multi-configuration long-chain phenyl amino acid compound

The invention relates to a method for synthesizing a multi-configuration long-chain phenyl amino acid compound. The method comprises the following steps: reacting a compound shown in a formula I witha compound shown in a formula II or an isomer thereof in

Controlling diastereoselectivity in the reactions of enantiomerically pure α-bromoacyl-imidazolidinones with nitrogen nucleophiles: Substitution reactions with retention or inversion of configuration

Diastereoselective substitution reactions of α-bromoacyl- imidazolidinones with nitrogen nucleophiles can be promoted with either retention or inversion of configuration by carrying out reactions under epimerising or non-epimerising conditions. The Royal Society of Chemistry 2005.

Inhibitors of cathepsin S

The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme (e.g., cathespin K). The pr

STEREOSELECTIVE PROCESS FOR THE SYNTHESIS OF (D)-2-AMINO-5-PHENYLPENTANOIC OR ALKYL ESTER THEREOF

The present invention provides a process for preparing a compound of formula (I); wherein R is a C1-C6 alkyl; or a salt thereof; comprising:(c) hydrolyzing (D,L)-N-acetyl-2-amino-5-phenylpentanoic acid with a suitable base in the pre

Treatment of insulin resistance with growth hormone secretagogues

This invention is directed to methods of treating insulin resistance in a mammal which comprise administering an effective amount of a compound of formula I, where the variables are defined in the specification, or the stereoisomeric mixtures, diastereomerically enriched, diastereomerically pure, enantiomerically enriched or enantiomerically pure isomers, or the pharmaceutically acceptable salts and prodrugs thereof to said mammal. The compounds of formula I are growth hormone secretagogues and as such are useful for increasing the level of endogenous growth hormone. In another aspect this invention provides certain intermediates which are useful in the synthesis of the foregoing compounds and certain processes useful for the synthesis of said intermediates and the compounds of formula I. This invention is further directed to methods comprising administering to a human or other animal a combination of a functional somatostatin antagonist such as an alpha-2 adrenergic agonist and a compound of formula I.

Tricyclic erythromycin derivatives

Compounds, or pharmaceutically acceptable salts and esters thereof, of the formula: wherein A, B, D and E, R1, R2, and Z are specifically defined, having antibacterial activity, pharmaceutical compositions containing said compounds, treatment of bacterial infections with such compositions, and processes for the preparation of the compounds.

Heterocyclic compounds

This invention is directed to compounds of the formula and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the Specification, which are growth hormone secretogogues and which increase the level of endogenous growth hormone. The compounds of this invention are useful for the treatment and prevention of osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair, attenuating protein catabolic response after a major operation, reducing cachexia and protein loss due to chronic illness, accelerating wound healing, or accelerating the recovery of burn patients or patients having undergone major surgery; improving muscle strength, mobility, maintanence of skin thickness, metabolic homeostasis or renal homeostasis. The compounds of the present invention are also useful in treating osteoporosis when used in combination with: a bisphosphonate compound such as alendronate; estrogen, premarin, and optionally progesterone; an estrogen agonist or antagonist; or calcitonin, and pharmaceutical compositions useful therefor. Further, the present invention is directed to pharmaceutical compositions useful for increasing the endogenous production or release of growth hormone in a human or other animal which comprises an effective amount of a compound of the present invention and a growth hormone secretagogue selected from GHRP-6, Hexarelin, GHRP-1, growth hormone releasing factor (GRF), IGF-1, IGF-2 or B-HT920. The invention is also directed to intermediates useful in the preparation of compounds of formula I.

SULFONAMIDE INHIBITORS OF MATRIX METALLOPROTEINASES

Sulfonamide compounds are described which are inhibitors of matrix metalloproteinases, particularly stromelysin-1 and gelatinase A (72 kD gelatinase). Also described are methods for the treatment of multiple sclerosis, atherosclerotic plaque rupture, aortic aneurism, heart failure, restenosis, periodontal disease, corneal ulceration, burns, decubital ulcers, chronic ulcers or wounds, cancer metastasis, tumor angiogenesis, arthritis, or other autoimmune or inflammatory disorders dependent upon tissue invasion by leukocytes using the compounds.